Valuation: Hunan Fangsheng Pharmaceutical Co., Ltd.

Capitalization 4.91B 677M 645M 598M 532M 959M 57.49B 1.06B 7.44B 2.75B 23.61B 2.54B 2.49B 103B P/E ratio 2024 *
19.9x
P/E ratio 2025 * 16.4x
Enterprise value 4.91B 677M 645M 598M 532M 959M 57.49B 1.06B 7.44B 2.75B 23.61B 2.54B 2.49B 103B EV / Sales 2024 *
2.68x
EV / Sales 2025 * 2.31x
Free-Float
62.16%
Yield 2024 *
0.22%
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.09%
1 week-0.97%
Current month-2.10%
1 month-9.39%
3 months+4.09%
6 months+0.45%
Current year+2.10%
More quotes
1 week
10.96
Extreme 10.96
11.50
1 month
10.68
Extreme 10.68
12.58
Current year
7.12
Extreme 7.12
13.58
1 year
7.12
Extreme 7.12
13.58
3 years
4.89
Extreme 4.89
14.73
5 years
4.77
Extreme 4.77
14.73
10 years
4.50
Extreme 4.5
21.70
More quotes
Director TitleAgeSince
Chief Executive Officer 51 2022-03-03
Director of Finance/CFO 50 2021-06-16
Chief Operating Officer 43 -
Manager TitleAgeSince
Director/Board Member 45 2015-07-02
Chairman 51 2022-03-03
Chairman 43 -
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.09%-0.97%+3.13%+105.32%677M
+0.45%+0.99%+46.45%+138.39%51.17B
-0.66%-2.26%+53.47%+112.76%31.17B
-0.18%-2.72%+40.01% - 18.83B
+0.42%-2.64%+21.54%+63.95%13.85B
+1.65%+2.02%+56.24%+113.01%11.55B
-.--%+0.14% - - 6.79B
-.--%-1.95% - - 5.73B
+0.15%-1.26%-33.88%-38.13%5.31B
-0.03%-0.23%+4.45%+20.22%5.24B
Average +0.17%-1.36%+23.93%+73.65% 15.03B
Weighted average by Cap. +0.16%-1.60%+40.57%+107.27%
See all sector performances

Financials

2024 *2025 *
Net sales 1.83B 252M 240M 223M 198M 357M 21.42B 396M 2.77B 1.02B 8.8B 948M 927M 38.38B 2.13B 294M 280M 259M 231M 416M 24.93B 461M 3.23B 1.19B 10.24B 1.1B 1.08B 44.68B
Net income 246M 33.99M 32.35M 29.98M 26.66M 48.13M 2.88B 53.34M 373M 138M 1.18B 128M 125M 5.17B 301M 41.45M 39.45M 36.56M 32.52M 58.7M 3.52B 65.05M 455M 168M 1.44B 156M 152M 6.3B
Net Debt - -
More financial data * Estimated data
Logo Hunan Fangsheng Pharmaceutical Co., Ltd.
Hunan Fangsheng Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company primarily operates its businesses through two segments. The Pharmaceutical Manufacturing Business segment mainly provides cardiovascular and cerebrovascular drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs and anti-infective drugs. The Company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue capsules, Lysine Vitamin B12 granules, Cefuroxime tablets, Jinying capsules, Pudilan anti-inflammatory tablets, Xiaoer Jingxing cough granules, Ezetimibe tablets, Xuanqi bone-strengthening tablets, Qiangli Loquat Paste (honey-refined), Qiangli Loquat Dew and others. The Others segment is mainly engaged in other businesses such as medical services, pharmaceutical commerce and drug sales.
Employees
1,686
More about the company
Date Price Change Volume
24-12-10 11.19 ¥ -0.09% 5,230,512
24-12-09 11.20 ¥ +0.09% 5,880,262
24-12-06 11.19 ¥ +0.81% 5,586,422
24-12-05 11.10 ¥ +0.45% 4,672,700
24-12-04 11.05 ¥ -2.21% 5,394,656

End-of-day quote Shanghai S.E., December 09, 2024

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
surperformance-ratings-light-chart HUNAN-FANGSHENG-PHARMACEUMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.19CNY
Average target price
14.42CNY
Spread / Average Target
+28.91%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603998 Stock